398 related articles for article (PubMed ID: 16470607)
1. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
Li YH; He YF; Jiang WQ; Wang FH; Lin XB; Zhang L; Xia ZJ; Sun XF; Huang HQ; Lin TY; He YJ; Guan ZZ
Cancer; 2006 Mar; 106(6):1320-5. PubMed ID: 16470607
[TBL] [Abstract][Full Text] [Related]
2. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
Yeo W; Chan PK; Ho WM; Zee B; Lam KC; Lei KI; Chan AT; Mok TS; Lee JJ; Leung TW; Zhong S; Johnson PJ
J Clin Oncol; 2004 Mar; 22(5):927-34. PubMed ID: 14990649
[TBL] [Abstract][Full Text] [Related]
3. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
4. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
[TBL] [Abstract][Full Text] [Related]
5. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis.
Lim ST; Fei G; Quek R; Lim LC; Lee LH; Yap SP; Loong S; Tao M
Eur J Haematol; 2007 Aug; 79(2):132-7. PubMed ID: 17635237
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.
He YF; Li YH; Wang FH; Jiang WQ; Xu RH; Sun XF; Xia ZJ; Huang HQ; Lin TY; Zhang L; Bao SP; He YJ; Guan ZZ
Ann Hematol; 2008 Jun; 87(6):481-5. PubMed ID: 18299831
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration.
Dai MS; Wu PF; Shyu RY; Lu JJ; Chao TY
Liver Int; 2004 Dec; 24(6):540-6. PubMed ID: 15566502
[TBL] [Abstract][Full Text] [Related]
8. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
Leaw SJ; Yen CJ; Huang WT; Chen TY; Su WC; Tsao CJ
Ann Hematol; 2004 May; 83(5):270-5. PubMed ID: 15060745
[TBL] [Abstract][Full Text] [Related]
9. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
10. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
[TBL] [Abstract][Full Text] [Related]
11. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
[TBL] [Abstract][Full Text] [Related]
12. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
Mimura N; Tsujimura H; Ise M; Sakai C; Kojima H; Fukai K; Yokosuka O; Takagi T; Kumagai K
Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
[TBL] [Abstract][Full Text] [Related]
13. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.
Hsu C; Hsiung CA; Su IJ; Hwang WS; Wang MC; Lin SF; Lin TH; Hsiao HH; Young JH; Chang MC; Liao YM; Li CC; Wu HB; Tien HF; Chao TY; Liu TW; Cheng AL; Chen PJ
Hepatology; 2008 Mar; 47(3):844-53. PubMed ID: 18302293
[TBL] [Abstract][Full Text] [Related]
14. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
Vassiliadis T; Garipidou V; Tziomalos K; Perifanis V; Giouleme O; Vakalopoulou S
Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
[TBL] [Abstract][Full Text] [Related]
16. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
17. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.
Cheng AL; Hsiung CA; Su IJ; Chen PJ; Chang MC; Tsao CJ; Kao WY; Uen WC; Hsu CH; Tien HF; Chao TY; Chen LT; Whang-Peng J;
Hepatology; 2003 Jun; 37(6):1320-8. PubMed ID: 12774010
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
Schnepf N; Sellier P; Bendenoun M; Zini JM; Sanson-le Pors MJ; Mazeron MC
J Clin Virol; 2007 May; 39(1):48-50. PubMed ID: 17368969
[TBL] [Abstract][Full Text] [Related]
19. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
20. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
